Serum macrophage migration-inhibitory factor as a diagnostic and prognostic biomarker for gastric cancer

Cancer

Volumn 115, Issue 23, 2009, Pages 5441-5449

  Xia, Harry Hua Xiang ^a,c   Yang, Yi ^a,d   Chu, Kent Man ^a   Gu, Qing ^a   Zhang, Yuan Yuan ^b   He, Hua ^a,e   Wong, Wai Man ^a   Leung, Suet Yi ^a   Yuen, Siu Tsan ^a   Yuen, Man Fung ^a   Chan, Annie O O ^a   Wong, Benjamin C Y ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b FUDAN UNIVERSITY   (China)

^c NOVARTIS PHARMA AG   (Switzerland)

^d JOHNS HOPKINS UNIVERSITY   (United States)

^e NONE

Author keywords

Carcinoembryonic antigen; Diagnosis; Gastric cancer; Macrophage migration inhibitory factor; Prognosis

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; MACROPHAGE MIGRATION INHIBITION FACTOR; MOLECULAR MARKER;

ADULT; AGED; ARTICLE; CANCER PATIENT; COHORT ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DYSPEPSIA; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY; STOMACH ADENOCARCINOMA; SURVIVAL RATE;

AGED; DYSPEPSIA; FEMALE; HUMANS; MACROPHAGE MIGRATION-INHIBITORY FACTORS; MALE; MIDDLE AGED; PROGNOSIS; STOMACH NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 72249100819     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24609     Document Type: Article

References (44)

1. Murray CJL, Lopez AD. Mortality by cause for 8 regions of the world: Global burden of disease study. Lancet. 1997;349:1269-1276. (Pubitemid 27192468)
2. Berrino F, Esteve J, Coleman MP. Basic issues in estimating and comparing the survival of cancer patients. IARC Scientific Publications. 1995;132:1-14.
3. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics: 2002. CA Cancer J Clin. 2005;55:74-108.
4. Leung WK, Wu MS, Kakugawa Y, et al. Screening for gastric cancer in Asia: current evidence and practice. Lancet Oncol. 9:279-287, 2008 Mar. (Pubitemid 351722947)
5. Xia HHX, Wong BCY, Lam SK. Helicobacter pylori infection and gastric cancer. Asian J Surg. 2001;24:217-1212
6. Lue H, Kleemann R, Calandra T, Roger T, Bernhagen J. Macrophage migration inhibitory factor (MIF): mechanisms of action and role in disease. Microb Infect. 2002;4:449-460. (Pubitemid 34270682)
7. Shimizu T, Abe R, Nakamura H, Ohkawara A, Suzuki M, Nishihira J. High expression of macrophage migration inhibitory factor in human melanoma cells and its role in tumor cell growth and angiogenesis. Biochem Biophys Res Com. 1999;264:751-758.
8. Bin Q, Johnson BD, Schauer DW, Casper JT, Orentas RJ. Production of macrophage migration inhibitory factor by human and murine neuroblastoma. Tumour Biol. 2002;23: 123-129. (Pubitemid 44858303)
9. Meyer-Siegler KL, Bellino MA, Tannenbaum M. Macrophage migration inhibitory factor evaluation compared with prostate specific antigen as a biomarker in patients with prostate carcinoma. Cancer. 2002;94:1449-1456. (Pubitemid 34212639)
10. Akbar SM, Abe M, Murakami H, et al. Macrophage migration inhibitory factor in hepatocellular carcinoma and liver cirrhosis; relevance to pathogenesis. Cancer Lett. 2001; 171:125-132. (Pubitemid 32772798)
11. Kamimura A, Kamachi M, Nishihira J, et al. Intracellular distribution of macrophage migration inhibitory factor predicts the prognosis of patients with adenocarcinoma of the lung. Cancer. 2000;89:334-341. (Pubitemid 30489881)
12. Bini L, Magi B, Marzocchi B, et al. Protein expression profiles in human breast ductal carcinoma and histologically normal tissue. Electrophoresis. 1997;18:2832-2841. (Pubitemid 28059956)
13. Mitchell RA, Bucala R. Tumor growth-promoting properties of macrophage migration inhibitory factor (MIF). Sem Cancer Biol. 2000;10:359-366. (Pubitemid 30828786)
14. Takahashi N, Nishihira J, Sato Y, et al. Involvement of macrophage migration inhibitory factor (MIF) in the mechanism of tumor cell growth. Mol Med. 1998;4:707-714. (Pubitemid 29051376)
15. Maaser C, Eckmann L, Paesold G, Kim HS, Kagnoff MF. Ubiquitous production of macrophage migration inhibitory factor by human gastric and intestinal epithelium. Gastroenterology. 2002;122:667-680. (Pubitemid 34173819)
16. Murakami H, Akbar SMF, Matsui H, Onji M. Macrophage migration inhibitory factor in the sera and at the colonic mucosa in patients with ulcerative colitis: clinical implications and pathogenic significance. Eur J Clin Invest. 2001;31:337-343. (Pubitemid 32328535)
17. de Jong YP, Abadia-Molina AC, Satoskar AR, et al. Development of chronic colitis is dependent on the cytokine MIF. Nat Immunol. 2001;2:1061-1106
18. Ohkawara T, Nishihira J, Taeda H, et al. Amelioration of dextran sulfate-induced colitis by anti-macrophage migration inhibitory factor antibody in mice. Gastroenterology. 2002;123:256-270. (Pubitemid 34747546)
19. Huang XR, Hui CWC, Chen YX, et al. Macrophage migration inhibitory factor is an important mediator in the pathogenesis of gastric inflammation in rats. Gastroenterology. 2001;121:619-630.
20. Xia HHX, Lam SK, Huang XR, et al. Helicobacter pylori infection is associated with increased expression of macrophage migration inhibitory factor by epithelial cells, T-cells and macrophages in gastric mucosa. J Infect Dis. 2004;190:293-302.
21. Xia HHX, Zhang ST, Lin MCM, Kung HF, Lam SK, Wong BCY. Expression of macrophage migration inhibitory factor in esophageal squamous cell carcinoma. Carcinogenesis. 2004;26:11-15.
22. He XX, Yang J, Ding YW, Liu W, Shen QY, Xia HHX. Increased epithelial and serum expression of macrophage migration inhibitory factor in gastric cancer: potential role of MIF in gastric carcinogenesis. Gut. 2006; 55:797-802. (Pubitemid 43764549)
23. Chan AOO, Lam SK, Chu KM, et al. Soluble E-cadherin is a valid prognostic marker in gastric carcinoma. Gut. 2001;48:808-811.
24. Chan AOO, Chu KM, Lam SK, et al. Soluble E-cadherin is an independent pretherapeutic factor for long-term survival in gastric cancer. J Clin Oncol. 2003;21:2288-2293.
25. Nishi M, Omori Y, Miwa K, eds. Japanese Research Society for Gastric Cancer. Japanese Classification of Gastric Carcinoma. Tokyo: Kanehara; 1995.
26. Lauren P. The 2 histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. Acta Pathol Microbiol Scand. 1965;64:31-49.
27. Wong BCY, Wong WM, Wang WH, et al. An evaluation of invasive and non-invasive tests for the diagnosis of Helicobacter pylori infection in Chinese. Aliment Pharmacol Ther. 2001;15:505-511. (Pubitemid 32242776)
28. Xia HHX, Wong BCY, Wong WM, et al. Optimal serological tests for the detection of Helicobacter pylori infection in Chinese population. Aliment Pharmacol Ther. 2002; 16:521-526. (Pubitemid 34214532)
29. Dixon MF, Genta RM, Yardley JH, Correa P. Classification and grading of gastritis. The updated Sydney system. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol. 1996;20:1161-1181.
30. Shun CT, Lin JT, Huang SP, Lin MT, Wu MS. Expression of macrophage migration inhibitory factor is associated with enhanced angiogenesis and advanced stage in gastric carcinomas. World J Gastroenterol. 2005;11:3767-3771.
31. Xia HH, Lam SK, Chan AO, et al. Macrophage migration inhibitory factor stimulated by Helicobacter pylori increases proliferation of gastric epithelial cells. World J Gastroenterol. 2005;11:1946-1950. (Pubitemid 40520990)
32. Beswick EJ, Pinchuk IV, Suarez G, Sierra JC, Reyes VE. Helicobacter pylori CagA-dependent macrophage migration inhibitory factor produced by gastric epithelial cells binds to CD74 and stimulates procarcinogenic events. J Immunol. 2006;176:6794-6801. (Pubitemid 43787862)
33. Shimizu N, Wakatsuki T, Murakami A, et al. Carcinoembryonic antigen in gastric cancer patients. Oncology. 1987;44:240-244. (Pubitemid 17117527)
34. Wobbes T, Thomas CM, Segers MF, Nagengast FM. Evaluation of 7 tumor markers (CA50, CA19-9, CA 19-9 TruQuant, CA 72-4, CA 195, carcinoembryonic antigen, and tissue polypeptide antigen) in the pretreatment sera of patients with gastric carcinoma. Cancer. 1992;69:2036-2041.
35. American Gastroenterological Association medical position statement: evaluation of dyspepsia. Gastroenterology 1998; 114:579-581. (Pubitemid 28141203)
36. Christie J, Shepherd NA, Codling BW, Valori RM. Gastric cancer below the age of 55: implications for screening patients with uncomplicated dyspepsia. Gut. 1997;41:513-517. (Pubitemid 27448784)
37. Canga C, Vakil N. Upper GI malignancy, uncomplicated dyspepsia, and the age threshold for early endoscopy. Am J Gastroenterol. 2002;97:600-603. (Pubitemid 34245886)
38. Wallace MB, Durkalski VL, Vaughan J, et al. Age and alarm symptoms do not predict endoscopic findings among patients with dyspepsia: a multicentre database study. Gut. 2001;49:29-34. (Pubitemid 32601876)
39. Maconi G, Kurihara H, Panizzo V, et al. Gastric cancer in young patients with no alarm symptoms: focus on delay in diagnosis, stage of neoplasm and survival. Scand J Gastroenterol. 2003;38:1249-1255. (Pubitemid 38096083)
40. Hammer J, Eslick GD, Howell SC, Altiparmak E, Talley NJ. Diagnostic yield of alarm features in irritable bowel syndrome and functional dyspepsia. Gut. 2004;53:666-672. (Pubitemid 38561444)
41. Bach JP, Rinn B, Meyer B, Dodel R, Bacher M. Role of MIF in inflammation and tumorigenesis. Oncology. 2008; 75:127-133.
42. Yasasever V, Camlica H, Duranyildiz D, Oguz H, Tas F, Dalay N. Macrophage migration inhibitory factor in cancer. Cancer Invest. 2007;25:715-719. (Pubitemid 350223175)
43. Lee H, Rhee H, Kang HJ, et al. Macrophage migration inhibitory factor may be used as an early diagnostic marker in colorectal carcinomas. Am J Clin Pathol. 2008;129:772-779.
44. Lee H, Rhee H, Kang HJ, et al. Macrophage migration inhibitory factor my b used as an early diagnostic marker in colorectal carcinomas. Am J Clin Pathol. 2007;129:772-779.